Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients

References

• Nicholls SJ, Hsu A, Wolski K, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. (in eng). 2010 May;vol. 55(21):pp. 2399–407.
   Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. (in eng). 2010 Nov;vol. 376(9753):1670–1681.
   Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. “Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial,”. JAMA. (in eng).2004 Mar;291(9):1071–1080.
   PubMed Web of Science ®Google Scholar
• Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. (in eng). 2012 Jan;366(1):54–63.
   PubMed Web of Science ®Google Scholar
• Moran AE, Forouzanfar MH, Roth GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the global burden of disease 2010 study. Circulation. (in eng). 2014 Apr;129(14):1483–1492.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American heart association. Circulation. (in eng). 2018 Mar;137(12):e67–e492.
   PubMed Web of Science ®Google Scholar
• Sidney S, Quesenberry CP, Jaffe MG, et al. “Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol. (in eng). 2016 August;1(5):594–599.
   PubMed Web of Science ®Google Scholar
• Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. (in eng) 2005 Oct;46(7):1225–1228.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. (in eng). 2010 Sep;304(12):1350–1357.
   PubMed Web of Science ®Google Scholar
• Dhindsa DS, Sandesara PB, Shapiro MD, et al. The evolving understanding and approach to residual cardiovascular risk management. Front Cardiovasc Med. (in eng). 2020;7:88.
   PubMed Web of Science ®Google Scholar
• Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. a report from the committee on vascular lesions of the council on arteriosclerosis, American heart association. Circulation. (in eng). 1995 Sep;92(5):1355–1374.
   PubMed Web of Science ®Google Scholar
• Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. (in eng). 2000 May;20(5):1262–1275.
   PubMed Web of Science ®Google Scholar
• Schoenhagen P, Ziada KM, Vince DG, et al. Arterial remodeling and coronary artery disease: the concept of “dilated” versus “obstructive” coronary atherosclerosis. J Am Coll Cardiol. (in eng). 2001 Aug;38(2):297–306.
   PubMed Web of Science ®Google Scholar
• Arbustini E, Dal Bello B, Morbini P, et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. (in eng). 1999 Sep;82(3):269–272.
   PubMed Web of Science ®Google Scholar
• Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. (in eng). N Engl J Med. 1987 May;316(22):1371–1375.
   PubMed Web of Science ®Google Scholar
• Puri R, Tuzcu EM, Nissen SE, et al. Exploring coronary atherosclerosis with intravascular imaging. Int J Cardiol. (in eng). 2013 Sep;168(2):670–679.
   PubMed Web of Science ®Google Scholar
• Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. (in eng). 2011 Jan;364(3):226–235.
   PubMed Web of Science ®Google Scholar
• Puri R, Nissen SE, Ballantyne CM, et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J. (in eng). 2013 Jun;34(24):1818–1825.
   PubMed Web of Science ®Google Scholar
• Puri R, Nissen SE, Shao M, et al. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J. (in eng). 2013 Nov;34(41):3182–3190.
   PubMed Web of Science ®Google Scholar
• Neefjes LA, Ten Kate G-JR, Rossi A, et al. CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia. Heart. (in eng). 2011 Jul;97(14):1151–1157.
   PubMed Web of Science ®Google Scholar
• Neefjes LA, Ten Kate G-JR, Alexia R, et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. (in eng). 2011 Dec;219(2):721–727.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. (in eng). 2015 Jun;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with Ezetimibe and Atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015 Aug;66(5):495–507. (in eng).
   PubMed Web of Science ®Google Scholar
• Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. (in eng). 2014 May;370(19):1809–1819.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. (in eng). 2014 May;311(18):1870–1882.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016 December;316(22):2373–2384. (in eng).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May;376(18):1713–1722. (in eng).
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after Acute coronary syndrome. N Engl J Med. (in eng). 2018 November;379(22):2097–2107.
   PubMed Web of Science ®Google Scholar
• Bayturan O, Kapadia S, Nicholls SJ, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. (in eng). 2010 Jun;55(24):2736–2742.
   PubMedGoogle Scholar
• Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. (in eng). 2005 Nov;112(22):3375–3383.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. (in eng). 2005 Jul;294(3):326–333.
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. (in eng). 2009 Dec;55(1):35–41.
   PubMedGoogle Scholar
• Puri R, et al. Non-HDL cholesterol and triglycerides: implications for coronary atheroma progression and clinical events. Arterioscler Thromb Vasc Biol. (in eng). 2016 Nov;36(11):2220–2228.
   PubMed Web of Science ®Google Scholar
• Elshazly MB, Quispe R, Michos ED, et al. Patient-level discordance in population percentiles of the total cholesterol to high-density lipoprotein cholesterol ratio in comparison with low-density lipoprotein cholesterol and non-high-density Lipoprotein cholesterol: the very large database of lipids study (VLDL-2B). (in eng). Circulation. 2015 Aug;132(8):667–676.
   PubMed Web of Science ®Google Scholar
• Elshazly MB, Nicholls SJ, Nissen SE, et al. Implications of Total to high-density lipoprotein cholesterol ratio discordance with alternative lipid parameters for coronary atheroma progression and cardiovascular events. Am J Cardiol. (in eng). 2016 Sep;118(5):647–655.
   PubMed Web of Science ®Google Scholar
• Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. (in eng). 2017 Feb;69(6):692–711.
   PubMed Web of Science ®Google Scholar
• Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. (in eng). 2016 November;36(11):2239–2245.
   PubMed Web of Science ®Google Scholar
• Shah NP, Wang Q, Wolski KE, et al. The role of lipoprotein (a) as a marker of residual risk in patients with diabetes and established cardiovascular disease on optimal medical therapy: post Hoc analysis of ACCELERATE. Diabetes Care. (in eng). 2020 Feb;43(2):e22–e24.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. (in eng). 2019 March;139(12):1483–1492.
   PubMed Web of Science ®Google Scholar
• Puri R, Ballantyne CM, Hoogeveen RC, et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: insights from SATURN. Atherosclerosis. (in eng). 2017 Aug;263:137–144..
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. (in eng). 2014 Feb;63(6):520–527.
   PubMed Web of Science ®Google Scholar
• Verbeek R, Hoogeveen RM, Langsted A, et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. (in eng). 2018 July;39(27):2589–2596.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. (in eng). 2020 January;382(3):244–255.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjærg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. (in eng). 2013 Sep;128(12):1298–1309.
   PubMed Web of Science ®Google Scholar
• Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, et al. Triglyceride-rich Lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation. (in eng). 2018 August;138(8):770–781.
   PubMed Web of Science ®Google Scholar
• Elshazly MB, Mani P, Nissen SE, et al. Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. Eur J Prev Cardiol. (in eng). 2019 Nov:2047487319887578. DOI:10.1177/2047487319887578.
   Web of Science ®Google Scholar
• Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. (in eng). 2014 Aug;384(9943):626–635.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Marshall EB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. (in eng). 2010 Apr;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Bosch J, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. (in eng). 2012 Jul;367(4):309–318.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. (in eng). 2019 January;380(1):11–22.
   PubMed Web of Science ®Google Scholar
• Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. Arterioscler Thromb Vasc Biol. (in eng). 2020 Mar:ATVBAHA119313286. DOI:10.1161/ATVBAHA.119.313286.
   Web of Science ®Google Scholar
• Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. (in eng). 2017 Dec;70(6):537–544.
   PubMed Web of Science ®Google Scholar
• Qamar A, Libby P, Bhatt DL. Targeting RNA to lower triglycerides: long strides from short molecules. Eur Heart J. (in eng). 2019 Sep;40(33):2797–2800.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Hofstetter L, Rimoldi SF, et al. Risk factor variability and cardiovascular outcome: JACC review topic of the week. J Am Coll Cardiol. (in eng). 2019 May;73(20):2596–2603.
   PubMed Web of Science ®Google Scholar
• Clark D, Nicholls SJ, St. John J, et al. Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. Eur Heart J. (in eng). 2018 Jul;39(27):2551–2558.
   PubMed Web of Science ®Google Scholar
• Chhatriwalla AK, Nicholls SJ, Wang TH, et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol. (in eng). 2009 Mar;53(13):1110–1115.
   PubMed Web of Science ®Google Scholar
• Clark D, Nicholls SJ, St John J, et al. Visit-to-visit blood pressure variability, coronary atheroma progression, and clinical outcomes. JAMA Cardiol. (in eng). 2019 Apr;4:437.
   Web of Science ®Google Scholar
• Nakanishi R, Ceponiene I, Osawa K, et al. Plaque progression assessed by a novel semi-automated quantitative plaque software on coronary computed tomography angiography between diabetes and non-diabetes patients: a propensity-score matching study. Atherosclerosis. (in eng). 2016 December;255:73–79.
   PubMed Web of Science ®Google Scholar
• Stegman B, Puri R, Cho L, et al. “High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care. (in eng). 2014 Nov;37(11):3114–3120.
   PubMed Web of Science ®Google Scholar
• Gracia M, Betriu Angels, Matrinez-Alonso M, et al. Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD. Clin J Am Soc Nephrol. (in eng). 2016 Feb;11(2):287–296.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. (in eng). 2017 September;377(12):1119–1131.
   PubMed Web of Science ®Google Scholar